Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Sparing T cells from inhibition Programmed cell death 1 (PD-1) is an inhibitory receptor that normally keeps T cell immune responses in check. Immunotherapy targeting PD-1 has proven successful for certain types of cancer, but it remains unclear how PD-1 is regulated. Sugiura et al. found that a costimulatory molecule, CD80, can restrict PD-1 function during the activation of T lymphocytes. Binding of CD80 to the PD-1 ligand PD-L1 in cis on primary activated dendritic cells interfered with the ability of PD-L1 to access PD-1 on T cells, which would otherwise have inhibited T cell activation. Functional insights into PD-L1–CD80 interactions may explain the outcomes of anti–PD-1 and anti–PD-L1 cancer therapy. Science , this issue p. 558
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, PD‐L1 can interact in cis with Cluster of differentiation 80 (CD80) to PD‐1 [276, 277, 278], which may disturb the PD‐L1 and PD‐1 interaction and the CTLA4 and CD80 interaction and also maintain the flexibility of CD80 to trigger the signaling of CD28 [277, 279].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [278]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Cited by
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
“I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
BackgroundCombination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Yang, R., Sun, L., Li, C.-F., Wang, Y.-H., Yao, J., Li, H., Yan, M., Chang, W.-C., Hsu, J.-M., Cha, J.-H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21099-2 · Cited by 632
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 535
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Tekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023739118 · Cited by 490
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R., Totpal, K., Chiu, H., Wu, Y., Comps-Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 459
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 383
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394
“1 cis interaction on DCs might prevent PD-L1 ligation to PD-1 on T cells (16), depending on the relative protein abundance of PD-L1 versus B7.”
BackgroundZhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 225
Kennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 218
Xu, L., Zou, C., Zhang, S., Chu, T. S. M., Zhang, Y., Chen, W., Zhao, C., Yang, L., Xu, Z., Dong, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01307-2 · Cited by 209
T follicular helper cells in germinal center B cell selection and lymphomagenesis
Mintz, M. A., & Cyster, J. G. (2020) · Immunological Reviews · doi:10.1111/imr.12860 · Cited by 204
Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 197
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 191
Agarwal, S., Aznar, M. A., Rech, A. J., Good, C. R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.-J. A., Ravikumar, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.001 · Cited by 185
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
“Therefore, PDL1/CD80 cis-binding on antigen-presenting cells (APCs) reduces PDL1 availability for trans-binding to PD1 expressed on T cells, leading to diminished PD1 inhibitory signalling 58 .”
BackgroundNiu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis
Kalfaoglu, B., Almeida-Santos, J., Tye, C. A., Satou, Y., & Ono, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589380 · Cited by 173
Xu, F., Fei, Z., Dai, H., Xu, J., Fan, Q., Shen, S., Zhang, Y., Ma, Q., Chu, J., Peng, F., et al. (2022) · Advanced Materials · doi:10.1002/adma.202106265 · Cited by 176
Kumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 186
Celis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.041 · Cited by 154
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
TUTTLE, J. L., Drescher, E., Campos, J. A. S., Emery, P., Greenwald, M., Kivitz, A., Rha, H., Yachi, P. P., Kiley, C., & Nirula, A. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2209856 · Cited by 159
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Khan, S. U., Fatima, K., & Malik, F. A. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10172-9 · Cited by 155
Targeting immune checkpoints in hematological malignancies
Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 113
Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
Lu, D., Ni, Z., Liu, X., Feng, S., Dong, X., Shi, X., Zhai, J., Mai, S., Jiang, J., Wang, Z., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/1919082 · Cited by 134
Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 144
VISTA: Coming of age as a multi-lineage immune checkpoint
ElTanbouly, M. A., Schaafsma, E., Noelle, R. J., & Lines, J. L. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13415 · Cited by 126
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
Rotman, J., den Otter, L. A. S., Bleeker, M. C. G., Samuels, S., Heeren, A. M., Roemer, M. G. M., Kenter, G. G., Zijlmans, H. J. M. A. A., van Trommel, N. E., de Gruijl, T. D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596825 · Cited by 115
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Javed, S. A., Najmi, A., Ahsan, W., & Zoghebi, K. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383456 · Cited by 122
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 100
Rafieerad, A., Yan, W., Alagarsamy, K. N., Srivastava, A., Sareen, N., Arora, R. C., & Dhingra, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202106786 · Cited by 103
PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity
Sugiura, D., Okazaki, I., Maeda, T. K., Maruhashi, T., Shimizu, K., Arakaki, R., Takemoto, T., Ishimaru, N., & Okazaki, T. (2022) · Nature Immunology · doi:10.1038/s41590-021-01125-7 · Cited by 108
Self-citationSoluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 106
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
Philips, E. A., García‐España, A., Tocheva, A. S., Ahearn, I. M., Adam, K. R., Pan, R., Mor, A., & Kong, X. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.011747 · Cited by 106
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells
Romero, Y., Wise, R., & Zolkiewska, A. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02437-2 · Cited by 92
Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases
Huang, C., Zhu, H., Yao, Y., Bian, Z.-H., Zheng, Y.-J., Li, L., Moutsopoulos, H. Μ., Gershwin, M. E., & Lian, Z. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102333 · Cited by 101
PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
Zhang, J., Yan, Y., Li, J., Adhikari, R., & Fu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00722 · Cited by 101
Zhao, X., Yuan, C., Wangmo, D., & Subramanian, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.036 · Cited by 96
Zhao, Y., Caron, C., Chan, Y.-Y., Lee, C. K., Xu, X., Zhang, J., Masubuchi, T., Wu, C., Bui, J. D., & Hui, E. (2023) · Immunity · doi:10.1016/j.immuni.2023.04.005 · Cited by 101
Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
Kleinendorst, S. C., Oosterwijk, E., Bussink, J., Westdorp, H., Konijnenberg, M., & Heskamp, S. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4332 · Cited by 87
Wang, D., Cui, Q., Yang, Y. J., Liu, A. Q., Zhang, G., & Yu, J. C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113541 · Cited by 94
Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 97
PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81
Targeting MHC-I inhibitory pathways for cancer immunotherapy
Wang, J., Qiao, L., Chen, X., & Aifantis, I. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.01.009 · Cited by 85
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
Curnock, A. P., Bossi, G., Kumaran, J., Bawden, L. J., Figueiredo, R., Tawar, R., Wiseman, K., Henderson, E., Hoong, S.-J., Gonzalez, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152468 · Cited by 81
Sasikumar, P. G., & Ramachandra, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.752065 · Cited by 80
Lin, Z., Xiong, Y., Meng, W., Hu, Y., Chen, L., Chen, L., Xue, H., Panayi, A. C., Zhou, W., Sun, Y., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.042 · Cited by 73
The PD-1:PD-L1 axis in Inflammatory Arthritis
Canavan, M., Floudas, A., Veale, D. J., & Fearon, U. (2021) · BMC Rheumatology · doi:10.1186/s41927-020-00171-2 · Cited by 82
Ren, X., Hui, Z., Zhang, J., Ren, Y., LI, X., Yan, C., Wang, T., Yu, W., Wang, T., Xiao, S., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05057-4 · Cited by 83
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 73
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
Engineered MXene Biomaterials for Regenerative Medicine
Zhang, S., Wang, L., Feng, Z., Wang, Z., Wang, Y., Wei, B., Liu, H., Zhao, W., & Li, J. (2025) · ACS Nano · doi:10.1021/acsnano.4c16136 · Cited by 76
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 73
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Kotanides, H., Li, Y., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 65
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 69
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Wang, Y., Zhou, Y., Yang, L., Lei, L., He, B., Cao, J., & Gao, H. (2023) · Advanced Science · doi:10.1002/advs.202303175 · Cited by 84
PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
Ishida, Y. (2020) · Cells · doi:10.3390/cells9061376 · Cited by 68
Suzuki, K., Tajima, M., Tokumaru, Y., Oshiro, Y., Nagata, S., Kamada, H., Kihara, M., Nakano, K., Honjo, T., & Ohta, A. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4947 · Cited by 65
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 73
PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation
Shimizu, K., Sugiura, D., Okazaki, I.-M., Maruhashi, T., Takegami, Y., Cheng, C., Ozaki, S., & Okazaki, T. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.012 · Cited by 63
Self-citationTargeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 67
Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist
Ng, K. W., Attig, J., Young, G. R., Ottina, E., Papamichos, S. I., Kotsianidis, Ι., & Kassiotis, G. (2019) · eLife · doi:10.7554/elife.50256 · Cited by 63
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Armengol, M., Santos, J. C., Fernández-Serrano, M., Profitós-Pelejà, N., Ribeiro, M. L., & Roué, G. (2021) · Cancers · doi:10.3390/cancers13020214 · Cited by 65
Wang, H., Ma, H., Sové, R. J., Emens, L. A., & Popel, A. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002100 · Cited by 53
Liu, Y., Liu, Q., Zhang, B., Chen, S., Shen, Y., Li, Z., Zhang, J., Yang, Y., Li, M., & Wang, Y. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01373-0 · Cited by 66
Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
Hor, J. L., Schrom, E. C., Wong-Rolle, A., Vistain, L. F., Shang, W., Dong, Q., Zhao, C. N., Jin, C., & Germain, R. N. (2025) · Nature · doi:10.1038/s41586-025-09440-x · Cited by 68
Han, B., Dong, L., Zhou, J., Yang, Y., Guo, J., Xuan, Q., Gao, K., Xu, Z., Lei, W., Wang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02898-4 · Cited by 57
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 55
Boosting Glioblastoma Therapy with Targeted Pyroptosis Induction
Fang, X., Chen, Z., Zhou, W., Li, T., Wang, M., Gao, Y., Ma, S., Feng, Y. J., Du, S., Lan, P., et al. (2023) · Small · doi:10.1002/smll.202207604 · Cited by 55
Lucas, E. D., Schafer, J. B., Matsuda, J. L., Kraus, M., Burchill, M. A., & Tamburini, B. A. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108258 · Cited by 58
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Wang, H., Sové, R. J., Jafarnejad, M., Rahmeh, S., Jaffee, E. M., Stearns, V., Torres, E. T. R., Connolly, R. M., & Popel, A. S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00141 · Cited by 51
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression
Lu, J., Wu, J., Mao, L., Xu, H., & Wang, S. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.003 · Cited by 51
Hata, K., Yanagihara, T., Matsubara, K., Kunimura, K., Suzuki, K., Tsubouchi, K., Eto, D., Ando, H., Uehara, M., Ikegame, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145814 · Cited by 53
Guo, X.-J., Lu, J., Zeng, H., Zhou, R., Sun, Q., Yang, G., Pei, Y.-Z., Meng, X., Shen, Y., Zhang, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705378 · Cited by 53
Zhou, Q., Yan, X., Zhu, H., Xin, Z., Zhao, J., Shen, W., Yin, W., Guo, Y., Xu, H., Zhao, M. F., et al. (2021) · Theranostics · doi:10.7150/thno.61677 · Cited by 55
CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation
Ahmed, A., Joseph, A. M., Zhou, J., Horn, V., Uddin, J., Lyu, M., Goc, J., Bank, J. L. C., Artis, D., Longman, R., et al. (2024) · Nature · doi:10.1038/s41586-024-07537-3 · Cited by 57
Maeda, N., Maruhashi, T., Sugiura, D., Shimizu, K., Okazaki, I., & Okazaki, T. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010379 · Cited by 49
Self-citationMechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
Westdorp, H., Sweep, M. W. D., Gorris, M. A. J., Hoentjen, F., Boers‐Sonderen, M. J., van der Post, R. S., van den Heuvel, M. M., Piet, B., Boleij, A., Bloemendal, H. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768957 · Cited by 54
Maurer, M. F., Lewis, K. E., Kuijper, J. L., Ardourel, D., Gudgeon, C. J., Chandrasekaran, S., Mudri, S., Kleist, K. N., Navas, C. L., Wolfson, M. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29286-5 · Cited by 48
Transmembrane domain–driven PD-1 dimers mediate T cell inhibition
Philips, E. A., Liu, J., Kvalvaag, A. S., Mørch, A. M., Tocheva, A. S., Ng, C., Liang, H., Ahearn, I. M., Pan, R., Luo, C. C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade6256 · Cited by 50
Suzuki, K., Yanagihara, T., Matsumoto, K., Kusaba, H., Yamauchi, T., Ikematsu, Y., Tanaka, K., Otsubo, K., Inoue, H., Yoneshima, Y., et al. (2020) · International Immunology · doi:10.1093/intimm/dxaa022 · Cited by 49
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Pathak, R., Pharaon, R. R., Mohanty, A. R., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020) · Cancers · doi:10.3390/cancers12123851 · Cited by 51
Xu, Y., Zhu, G., Maroun, C. A., Wu, X., Huang, D., Seiwert, T. Y., Liu, Y., Mandal, R., & Zhang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645170 · Cited by 50
PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies
Nishimura, C., Pulanco, M. C., Cui, W., Lu, L., & Zang, X. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.10.004 · Cited by 48
Targeting persistently activated inflammatory microenvironment to promote chronic wound healing
Dai, Y., & Chen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708358 · Cited by 47
Das, D., Ghosh, S., Maitra, A., Biswas, N. K., Panda, C. K., Roy, B., Sarin, R., & Majumder, P. P. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0782-2 · Cited by 46
Metadata
- Authors
- Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T.
- Affiliations
- Institute of Advanced Medical Sciences, Tokushima University (JP)
- Corresponding author
- Sugiura, Daisuke
- Maruhashi, Takumi
- Okazaki, Il-mi
- Shimizu, Kenji
- Maeda, Takeo K.
- Okazaki, Taku
- ORCID
- Venue
- Science
- Published
- 2019-05-10
- Volume
- 364
- Issue
- 6440
- Pages
- 558-566
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2936616584
- Cited by
- 386
- References
- 40
- Citations by year
- 2026: 44 · 2025: 40 · 2024: 61 · 2023: 49 · 2022: 52 · 2021: 63 · 2020: 53 · 2019: 23
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP18am0301007)
- Japan Society for the Promotion of Science (JP18H05417)
- Core Research for Evolutional Science and Technology, Japan Science and Technology Agency
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, CD80, T cell activation, T cell suppression, costimulation, dendritic cells, anti-PD-1 therapy, PD-L1 blockade, cancer immunotherapy, immune checkpoint regulation
- MeSH terms
- Animals, Dendritic Cells, Humans, Immunotherapy, Lymphocyte Activation, Mice, Mutant Strains, Neoplasms, Protein Binding, T-Lymphocytes, Autoimmunity, CD28 Antigens, B7-1 Antigen, Mice, Gene Knock-In Techniques, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.